# Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment

> **NCT07033182** · PHASE1 · COMPLETED · sponsor: **Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd** · enrollment: 24 (actual)

## Conditions studied

- Infections Caused by Anaerobic Bacteria
- Renal Impairment

## Interventions

- **DRUG:** Levornidazole Disodium Phosphate for Injection

## Key facts

- **NCT ID:** NCT07033182
- **Lead sponsor:** Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-30
- **Primary completion:** 2024-04-07
- **Final completion:** 2024-07-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07033182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07033182, "Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07033182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*